Home
ReportReportDue to this backdrop, BD has already increased its US Posiflush production capacity. The company said that it has grown capacity by almost 10% in 2025 by bringing its total output of the prefilled flush syringes in the US to be more than 750 million units.
In 2024, BD added new needle and syringe production lines at its plant in Nebraska and Connecticut, which were a part of over a $10mn investment. The latest investment comes three months after BD remarked that it was going to invest $2.5bn in US manufacturing in the next five years.
It is well to be noted that this week’s $35mn commitment happens to be a part of a series of vows by companies to invest in manufacturing within the US, due to the growing threat and imposition of tariffs. Yet BD has also warned that tariffs are actually causing it to relocate some of its production lines from Nebraska to overseas facilities.
The CEO of BD, Tom Polen, has explained how tariffs are moving some of its production out of the US at an event that was hosted by Golden Sachs in June this year.
Pollen had said that historically, their flush syringes always came out of Columbus, Nebraska, and then they would ship those to China. They have a facility in China now that is going to source just for China. He added that there is indeed more downside to tariff impacts from a US manufacturing perspective when it comes to the medtech industry as compared to others.
MHRA Wants Fast Patient Access to Innovative Medical DevicesMHRA Wants Fast Patient Access to Innovative Medical DevicesMHRA Wants Fast Patient Access to Innovative Medical Devices
Healthcare is awash in data – medical device data, electronic patient records, public-health surveillance data, clinical data, wearable data and more. By transforming it into meaningful and actionable information, MedTech companies can move up the value chain and gain a competitive advantage in a global digital health market projected to reach $US1 trillion by 2032. However, digital health poses data management challenges. Interoperability barr
In an exclusive interview with Hospital & Healthcare Management, Ryan Graham, CPHIT, Vice President, Practice Operations & Value-Based Care, and Zia Khan, MD, Chief Medical Officer for Privia Medical Group — Georgia, provided insightful details about Privia Health’s innovative approach to diabetes care management. Here are the key highlights:
